Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MAIA BiotechnologyMAIA -3.62%33 OCF Yield % is -27.89 as of Aug. 29, 2026. GuruFocus rates MAIA with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, MAIA Biotechnology ranks worse than 75.09% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
MAIA Biotechnology OCF Yield % Related Terms
MAIA Biotechnology OCF Yield % Historical Data
* Premium members only.
The historical data trend for MAIA Biotechnology's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MAIA Biotechnology's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MAIA Biotechnology OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's OCF Yield % distribution charts can be found below:
* The bar in red indicates where MAIA Biotechnology's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAIA Biotechnology (MAIA) has a OCF Yield % of -27.89 as of Aug. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on MAIA Biotechnology and its competitors. According to the industry distribution chart, MAIA Biotechnology ranks #1058 out of 1409 companies in the Biotechnology industry, placing it in the top 75.1%.
Is MAIA Biotechnology's OCF Yield % too high?
MAIA Biotechnology's current OCF Yield % is -27.89. Based on the distribution chart, MAIA Biotechnology ranks #1058 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MAIA Biotechnology has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does MAIA Biotechnology's OCF Yield % compare to GANX and PYPD?
According to the Biotechnology industry distribution chart, MAIA Biotechnology ranks #1058 out of 1409 companies for OCF Yield %. This places MAIA Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on MAIA Biotechnology and its competitors. MAIA Biotechnology's current OCF Yield % is -27.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MAIA Biotechnology stock overvalued right now?
MAIA Biotechnology (MAIA) has a current OCF Yield % of -27.89. The current OCF Yield % is -27.89. MAIA Biotechnology's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For MAIA Biotechnology (MAIA), the current OCF Yield % is -27.89 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
33GF Score
Get the complete analysis for MAIA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAIA has been successfully added to your 
